secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2021-07-30T23:59:59+00:00
Accession:  0001564590-21-039326
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q2 revenue $826M (+30% reported, +25% organic); raises FY 2021 guidance
-----------------------------------------------------------------------------

- EPS of $2.34, up 36% as reported and 33% comparable basis.
- CAG Diagnostics recurring revenue grew 30% reported, 26% organic.
- 2021 revenue guidance raised to $3,170M-$3,205M (17%-18.5% reported growth).
- 2021 EPS outlook raised to $8.20-$8.36; operating margin forecast 28.6%-29.1%.
- U.S. same-store clinical visit growth 13% in Q2; premium instrument placements doubled YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000156459021039326/0001564590-21-039326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000156459021039326/idxx-8k_20210730.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-039326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer